Biosensics LLC

Biosensics LLC, a Newton, Massachusetts-based small business structured as a limited liability partnership, develops and commercializes wearable sensors, cloud-based digital health platforms, and AI-driven medical imaging software for federal research and development agencies, competing as a prime contractor exclusively on federal research grants and SBIR contracts under total small business set-asides.

Biosensics operates in federal biomedical research and development, with a capability portfolio anchored on proprietary wearable sensor platforms (PAMSYS, PAMSYS ULM, HDWEAR, MGWEAR, and ODALERT) that enable remote monitoring of motor function, cognitive decline, and disease progression in neurodegenerative and rare diseases, paired with cloud-based analytics and digital biomarker collection tools (BIODIGIT HOME and BIODIGIT CLOUD). Representative recent work includes a $2 million definitive contract from the National Institute on Drug Abuse for technological development and validation of remote measures for use in clinical trials in individuals with rare diseases, awarded May 2024 with ultimate completion May 2027 and invoiced at $280 thousand across 0.9 FTEs in FY2024 at a derived rate of $148.31 per hour; a $314,362 federal grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) awarded September 2026 to develop digital assessment tools for motor skills in infants and young boys with Duchenne muscular dystrophy using wearable sensors; and a $5.17 million Cooperative Agreement from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded September 2025 in partnership with Massachusetts General Hospital and Johns Hopkins University to develop and qualify digital health monitoring technologies for Progressive Supranuclear Palsy and Dementia with Lewy Bodies through the FDA Biomarker Qualification Program.

The vendor's customer concentration reflects NIH institutional dominance. The top five customer agencies account for 72 percent of recent awards by count: the National Institute on Aging leads with 20 awards, followed by the broader NIH organization (8 awards), the Army Medical Command (4 awards, $600 thousand combined potential value), the National Institute on Drug Abuse (3 awards, $2 million combined potential value), and the Defense Health Agency (3 awards, $157 thousand combined potential value). By dollars, the National Institute on Drug Abuse, Army Medical Command, National Cancer Institute, and National Center for Advancing Translational Sciences anchor the top tier, with the Veterans Health Administration contributing a $225 thousand award. The vendor has worked with 14 distinct customer agencies across 53 total awards. All awards are prime contracts or grants; the vendor does not operate as a subcontractor. Biosensics competes exclusively under total small business set-asides on federal research contracts and SBIR solicitations; no full-and-open competition is present in the award footprint.

Activity has remained modest and flat. The vendor received 3 awards in 2022, 4 in 2023, 4 in 2024, 2 in 2025, and 1 in 2026, with combined potential value across all 53 awards standing at $3.7 million but combined obligated dollars of $97 million, reflecting the multi-year contract and grant nature of the portfolio and significant milestone payments or staged funding streams. Five awards (combined potential value $2 million) have ultimate completion dates within the next twenty-four months and therefore face recompete exposure in that window. On SCI-reportable federal service contracts above the $150,000 threshold, Biosensics invoiced $280 thousand in FY2024 across 0.9 FTEs; no SCI-reportable invoicing appears in FY2025. SCI data is a narrow slice of the vendor's federal activity — it excludes grants, research contracts, goods, and micro-purchases that constitute the bulk of Biosensics' federal footprint, so SCI figures substantially understate federal revenue and workforce.

The vendor's work spans applied research and product development across NAICS codes anchored on Research and Development in the Physical, Engineering, and Life Sciences (7 awards) and Biotechnology (2 awards). Federal grant partnerships include Massachusetts General Hospital and Johns Hopkins University on the National Institute on Aging cooperative agreement for neurodegenerative disease monitoring, Baylor College of Medicine on an NIDA-funded Cooperative Agreement for development of ODALERT, an opioid overdose detection wearable device, and Beth Israel Deaconess Medical Center on an NIH-funded project to develop a cloud-based platform for automatic screening of vertebral compression fractures.